5/4 RegenMD

RegenMD         CIRM: California stem cell funding institute may fund clinical trial May 3, 2011 at 9:44 PM   By Eryn Brown, Los Angeles Times The California Institute for Regenerative Medicine may reach a milestone of sorts Wednesday when its governing board will vote on whether to fund a clinical trial involving a therapy derived from stem cells. ... See all stories on this topic »         City docs promise to slow down ageing May 3, 2011 at 5:11 PM   Prescribing a combo of dietary practices, lifestyle changes, weight loss programmes and other complex therapies targeted at reversing cellular ageing, these doctors use 'regenerative medicine' to help patients feel and perform the best they can at any ... See all stories on this topic »         3D Printers Could Be Used To Create Custom Organs May 3, 2011 at 2:18 PM   Researchers at the Wake Forest University Institute for Regenerative Medicine say that the printers could be used to create custom organs designed specifically for your body. And if that sounds like science fiction, they've actually already created ... See all stories on this topic »         ProFibrix Raises $22M to Progress Fibrocaps Topical Sealant into Phase III May 3, 2011 at 11:27 AM   The firm is exploiting its expertise in fibrinogen technology to develop and market products for the hemostasis and regenerative medicine markets. Lead clinical-stage product, Fibrocaps, is based on a mixture of two essential blood-clotting proteins, ... See all stories on this topic »         Tomorrow's Technology Today May 3, 2011 at 8:52 AM   Expressing his views about this trend Dr Samuel JK Abraham, Director, Nichi-In Centre for Regenerative Medicine (NCRM), Chennai says, "I guess its because of the growing number of liposuction procedures mainly for aesthetic reasons during which ... See all stories on this topic » Express Healthcare         Cytori Appoints Tommy G. Thompson to its Board; Names Lloyd Dean Chairman May 3, 2011 at 6:52 AM   Cytori and its regenerative medicine platform technology is incredibly promising and I am excited to be able to help and broaden its application and use around the world and in particular, here in the US," said Mr. Thompson. "It's an exciting time at ... See all stories on this topic »         Juventas completes Phase I trial testing JVS-100 in HF patients May 3, 2011 at 3:56 AM   Juventas Therapeutics, a regenerative medicine company, has competed a Phase I clinical trial evaluating the safety and efficacy of JVS-100, an encoder of Stromal-cell Derived Factor (SDF-1) that can promote tissue repair through the recruitment of ... See all stories on this topic »             This email was sent to regenmd@gmail.com. Delivered by Feed My Inbox PO Box 682532 Franklin, TN 37068 Account Login Unsubscribe Here